PDF(Pubmed)
Abstract：
Liquid biopsies including pleural fluid or plasma are commonly applied for patients with advanced non-small cell lung cancer (NSCLC) and pleural effusion (PE) to guide the treatment. ALK-TKIs are the first options for patients with ALK-positive mutations and combining ALK-TKIs with angiogenic agents may improve survival. We report here one case with ALK-positive lung adenocarcinoma in which the patient achieved a prolonged progression-free survival (PFS) of 97 months after undergoing precise pleural effusion NGS and receiving combined bevacizumab treatment following multiple-line ALK-TKI resistance.
摘要：
包括胸腔积液或血浆的液体活检通常用于晚期非小细胞肺癌（NSCLC）和胸腔积液（PE）的患者，以指导治疗。ALK-TKIs是ALK阳性突变患者的首选方案，ALK-TKIs与血管生成剂联合使用可能会提高生存率。我们在这里报告了一例ALK阳性肺腺癌，其中患者在接受精确的胸腔积液NGS并在多线ALK-TKI耐药后接受贝伐单抗联合治疗后，获得了97个月的延长的无进展生存期（PFS）。
